Featured Publications
Ketamine versus ECT for Nonpsychotic Treatment-Resistant Major Depression
Anand A, Mathew S, Sanacora G, Murrough J, Goes F, Altinay M, Aloysi A, Asghar-Ali A, Barnett B, Chang L, Collins K, Costi S, Iqbal S, Jha M, Krishnan K, Malone D, Nikayin S, Nissen S, Ostroff R, Reti I, Wilkinson S, Wolski K, Hu B. Ketamine versus ECT for Nonpsychotic Treatment-Resistant Major Depression. New England Journal Of Medicine 2023, 388: 2315-2325. PMID: 37224232, DOI: 10.1056/nejmoa2302399.Peer-Reviewed Original ResearchConceptsTreatment-resistant major depressionPatient-reported qualityElectroconvulsive therapyMajor depressionECT groupKetamine groupTreatment phaseMusculoskeletal adverse effectsSubanesthetic intravenous ketamineWeeks of treatmentInitial treatment phaseIntravenous ketamineSecondary outcomesPrimary outcomeNoninferiority marginTrial groupECT clinicsNoninferiority trialPatientsComparative effectivenessKetamineClinical sitesAdverse effectsDepressionThree times
2023
Cognitive behavioral therapy following esketamine for major depression and suicidal ideation for relapse prevention: The CBT-ENDURE randomized clinical trial study protocol
Kitay B, Murphy E, Macaluso M, Corlett P, Hershenberg R, Joormann J, Martinez-Kaigi V, Nikayin S, Rhee T, Sanacora G, Shelton R, Thase M, Wilkinson S. Cognitive behavioral therapy following esketamine for major depression and suicidal ideation for relapse prevention: The CBT-ENDURE randomized clinical trial study protocol. Psychiatry Research 2023, 330: 115585. PMID: 37935086, DOI: 10.1016/j.psychres.2023.115585.Peer-Reviewed Original ResearchMeSH KeywordsCognitive Behavioral TherapyDepressionDepressive Disorder, MajorHumansRandomized Controlled Trials as TopicSuicidal IdeationConceptsCognitive behavioral therapyMajor depressionSuicidal ideationRelapse preventionBehavioral therapyStudy protocolHigh riskClinical trial study protocolLong-term treatment approachKey secondary outcomesTrial study protocolHigh relapse rateHigh-risk populationSignificant suicidal ideationHospital dischargeSecondary outcomesPrimary outcomeRelapse rateFeasibility trialEsketamineTreatment approachesPatientsSuicide attemptsTherapySupplemental indications
2021
Evaluating the Role of Ketamine/Esketamine in the Management of Major Depressive Disorder with Suicide Risk
Nikayin S, Sanacora G. Evaluating the Role of Ketamine/Esketamine in the Management of Major Depressive Disorder with Suicide Risk. CNS Drugs 2021, 35: 1069-1079. PMID: 34491545, DOI: 10.1007/s40263-021-00851-8.Peer-Reviewed Original ResearchMeSH KeywordsAntidepressive AgentsClinical Trials, Phase III as TopicDepressive Disorder, MajorDisease ManagementHumansKetamineRisk AssessmentSuicidal IdeationConceptsMajor depressive disorderDepressive disorderSuicidal ideationFirst large-scale trialKetamine/esketamineTreatment of patientsRole of ketamineSerious suicidal thoughtsActive suicidal ideationLarge-scale trialsAcute settingImminent riskClinical trialsPivotal studiesEsketamineClinical meaningfulnessRecent approvalPatientsSuicidal thoughtsSuicide riskNovel therapeuticsDisordersTrialsDepressed individualsIdeation